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RNAi could protect experimental animals from Foot-and-mouth disease virus (FMDV), but pivotal issue
is delivery of RNAi. In this study, shRNA recombinant lentiviral plasmid RNAi-LT6 targeting VP1 of
FMDV, which strongly suppressed the transient expression of a FLAG-tagged VP1 protein in 293T cells
and signiﬁcantly inhibited viral replication in BHK-21 cells, was screened and transfected into bovine
fetal ﬁbroblast cells. With subsequent somatic cell cloning, three 4-month-old transgenic fetuses were
obtained, and integration into chromosome and expression of shRNA in primary transgenic tongue
epithelium cells were conﬁrmed by Southern hybridization and Northern assay, respectively. shRNA
signiﬁcantly suppressed viral RNA synthesis and viral replication in primary transgenic tongue
epithelium cells after inoculation of 200 TCID50 of FMDV. The results suggested that transgenic cloning
may be a useful tool for RNAi delivery and RNAi anti-viral strategy, and RNAi-LT6 could be a candidate
shRNA used for preparation of transgenic cattle against FMDV.
& 2013 Elsevier Inc. All rights reserved.Introduction
Foot-and-mouth disease virus (FMDV), the prototype member of
the Aphthovirus genus, is a single-stranded, positive-sense RNA
genome virus, which causes Foot-and-mouth disease (FMD) of many
cloven-hoofed animals, including cattle, swine, and sheep. The
disease causes substantial lost of milk in dairy cattle and reduction
in the growth rate of meat animals. The way of its control in an
enzootic area is strict vaccination and restricted animal movement
(Balamurugan et al., 2004). The killed FMD vaccine has been
successfully used to reduce the number of disease outbreaks in
many parts of the world where the disease is enzootic. Although
protective immune responses against FMDV can be helpful, the viral
rapid replication and spread could exceed development of immune
defense and surmount the immune system. At the same time, FMDV
can also evade innate immune responses through its ability to shut
down cellular protein synthesis (Summerﬁeld et al., 2009), andll rights reserved.
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.interrupt the innate immune response via evolving mechanisms to
break off the normal function of dendritic cells and natural killer
cells (Golde et al., 2008). In addition, antigenic diversity and
continuous co-circulation of different serotypes in a given geogra-
phical region and persistence of virus in infected or vaccinated
animals make the disease very difﬁcult to control (Balamurugan
et al., 2004). Therefore, novel antiviral control approaches are being
developed and tested, and integrated FMD control strategies are
being designed in an effort to eliminate or more effectively control
FMD worldwide.
RNA interference (RNAi) using short hairpin RNA (shRNA) is an
antiviral approach that could be used to protect either animal
species (Bitko and Barik, 2001; Gitlin et al., 2002) or plants
(Waterhouse et al., 2001) from viruses. shRNAs are highly speciﬁc
tools to silence gene expression (Leonard and Schaffer, 2006) and
have been widely used to inhibit FMDV in vitro and/or in vivo
(Chen et al., 2004, 2006; Cong et al., 2010a; de los Santos et al., 2005;
Joyappa et al., 2009; Kahana et al., 2004; Liu et al., 2005; Lv et al.,
2009; Wang et al., 2012). However, pivotal issues of RNAi ther-
apeutics are delivery, speciﬁcity and stability of the RNAi reagents.
Of these, delivery is currently considered the biggest hurdle
(Perrimon et al., 2010). In fact, transgenic mice with shRNA targeting
FMDV were generated, and showed much less susceptible to the
challenge of FMDV as compared to the control mice (Wang et al.,
2010). However, no studies of transgenic shRNA targeting FMDV
H. Wang et al. / Virology 439 (2013) 115–121116in cloven-hoofed animals have been reported. Whereas expression
of lysostaphin in bovine mammary combated mastitis and protected
transgenic cattle from the challenges of Staphylococcus aureus in
mammary gland (Donovan et al., 2005; Kerr and Wellnitz, 2003;
Wall et al., 2005). Therefore, it is possible to address disease
problems in agriculturally important species using transgenic tech-
nology (Donovan et al, 2005), and genetic engineering can provide a
viable tool for enhancing resistance to disease and improve the well-
being of livestock.
In this study, RNAi-LT4, RNAi-LT5 and RNAi-LT6 targeting VP1
gene were synthesized as small hairpin RNA (shRNA) and con-
structed into Lenti-virus plasmid. All shRNAs could partly or
signiﬁcantly silence VP1 gene in 293T cells and suppressed
replication of FMDV in BHK-21 cells. RNAi-LT6 recombinant
Lenti-virus plasmid was then transfected into bovine fetal ﬁbro-
blast cells, with subsequent somatic cell cloning, three transgenic
bovine fetuses stably expressing shRNA were obtained, and their
primary tongue epithelium cells were used to evaluate potential
anti-viral capability of shRNA after the challenge of FMDV.Results
shRNAs inhibiting transient expression of VP1 in 293T cells
Three lentiviral shRNAs targeting VP1 of FMDV type Asia 1,
RNAi-LT4, RNAi-LT5 and RNAi-LT6, were constructed. pcDNA3-
FLAG-VP1 plasmid was co-transfected into 293T cells, along with
each shRNA recombinant lentiviral vectors. Expression of FLAG-
VP1 protein was determined by Western Blotting. As shown in
Fig. 1A, all shRNAs targeting VP1 signiﬁcantly inhibited transient
expression of FLAG-VP1 as compared to LacZ shRNA control.
RNAi-LT6 almost completely eliminated expression of VP1. These
results strongly suggested a direct role of shRNAs in speciﬁcally
blocking transient expression of VP1 protein in 293T cells.
shRNA silencing viral VP1 gene and inhibiting FMDV replication
in BHK-21 cells
We next determined whether shRNAs could block natural
expression of viral VP1 gene and inhibit FMDV replication. TheFlag-VP1
β-actin
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Fig. 1. shRNA targeting viral VP1 gene and inhibiting replication of FMDV in vitro: cell l
lentiviral plasmids were separated by SDS-PAGE, and then analyzed by Western blotting
repeated (A); BHK-21 cells stably expressing shRNA were cultured in 12-well plates in fo
strain. 48 h after FMDV inoculation, the cells and virus were collected, and mRNA expres
viral titer was determined after incubation by TCID50, the inhibition of viral replica
percentage of average TCID50 in treated cells to that in LacZ shRNA expressed controlBHK-21 cell lines stably expressing shRNAs were sorted by
ﬂuorescence-activated cell sorter (FACS) analysis based on shRNA
recombinant H1 lentiviral plasmids encoding eGFP. The stable cell
clones were inoculated with 200 TCID50 of the FMDV strain, VP1
mRNA expression and viral titers were determined. As shown in
Fig. 1B, VP1 mRNA expression was inhibited by all shRNAs, and
strongly degraded by RNAi-LT6 as compared to control shRNA
(LacZ). b-actin mRNA expression by contrast was not altered by
either shRNA. By TCID50 Assay, RNAi-LT4 inhibited over 60% of viral
replication as compared to LacZ control, while RNAi-LT5 showed
more than 84% inhibition of viral replication, and RNAi-LT6
inhibited over 95% of viral replication (Fig. 1C). Thus, RNAi-LT6
speciﬁcally and signiﬁcantly targeted VP1 mRNA and reduced viral
replication in vitro.
Development of reconstructed shRNA transgenic embryos
shRNA recombinant lentiviral plasmid RNAi-LT6 was then
transfected into bovine fetal ﬁbroblast cells. 14 days later,
transgenic bovine fetal ﬁbroblast cell clones were selected based
on eGFP expression, and shRNA positive transgenic cell clones
were conﬁrmed by PCR and sequencing. After shRNA transgenic
cells from a same cell clone were transferred into enucleated
oocyte cytoplasts, total of 216 reconstructed oocytes were
obtained based on eGFP expression. The fusion, cleavage and
blastocyst development rates were 83.8% (181/216), 82.3% (149/
181), and 30.2% (45/149), respectively. Forty-two blastocysts
were ﬁnally screened based on their development, and then
transferred to 21 synchronized recipient cows. Pregnancy rates
at 60 days were 38.1% (8/21). Since the major focus of this study is
to evaluate the efﬁciency of FMDV shRNA targeting after trans-
genic delivery, three 4-month-old cloning fetuses were obtained
after pregnancy for 4 months, instead of adult animals, for the
sake of saving time and money.
shRNA integration into chromosome of cloned bovine fetuses and
expression in primary transgenic tongue epithelium cells
The expected shRNA fragments could be ampliﬁed from the
genomic DNA of cloned fetuses, but not from normal fetus, as120
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Fig. 2. shRNA integration into chromosome of cloned fetuses and expression in primary transgenic tongue epithelium cells: the genomic DNA from the ear tissue of one
normal (lane 1) and three transgenic (lane 2, 3, and 4) fetuses were extracted, and used as the template for PCR ampliﬁcation, there was positive band in cloned fetuses, but
not in the normal fetus (A), shRNA transgenic fragment was then conﬁrmed by DNA sequencing. The genomic DNAs were digested into smaller fragments with excess
amounts of XhoI and ApaI for Southern Blotting, and were hybridized with probe (B). The expression of shRNA in primary transgenic bovine tongue epithelium cells was
determined by Northern analyses (C), b-actin as a quantitative control. Three experiments were independently repeated.
H. Wang et al. / Virology 439 (2013) 115–121 117shown in Fig. 2A, and then conﬁrmed by DNA sequencing.
Furthermore, the shRNA integration into chromosome of cloned
fetuses and expression in primary transgenic tongue epithelium
cells were conﬁrmed by Southern Blotting and Northern, respec-
tively, whereas there was no expected band detected in normal
fetus or cells (Fig. 2B and C). Thus, shRNA was indeed integrated
into chromosome and expression in tongue epithelium cells of
transgenic bovine fetuses.
RNAi-mediated degradation of viral RNA in primary transgenic
bovine tongue epithelium cells
The primary tongue epithelium cells were inoculated with 200
TCID50, and viral samples were taken at designated time points
and viral RNA was determined by real-time RT-PCR. The repre-
sentive result of three independent experiments was shown as in
Fig. 3A, there was signiﬁcant difference in relative amounts of
viral RNA between cells from three transgenic (T1, T2, and T3) and
normal fetuses (N1, N2, and N3). The average viral RNA in
transgenic cells were 1.9103 and 2.7104 at 24 and 48 h,
respectively, as compared to 2.4104 and 2.7105 in normal
cells (Fig. 3B). So shRNAs expression in transgenic cells inhibited
91.9% and 90.1% of viral RNA replication as compared to normal
control cells (Fig. 3C). Thus, transgenic shRNAs in primary
transgenic tongue epithelium cells signiﬁcantly degraded
viral RNA.
RNAi-mediated protection of primary transgenic bovine tongue
epithelium cells from FMDV infection
Viral replications were determined, as shown in Fig. 4A,
although there was no difference in viral titer among cells
expressing three transgenic shRNA (T1, T2, and T3), or among
corresponding normal controls (N1, N2, and N3), signiﬁcance
exists when transgenic cells were compared to the normal
controls. The average viral titers in three normal primary bovine
fetus tongue epithelium cells were about 9.6105 and 7.2106
TCID50 at 24 and 48 h, respectively, whereas the average titers in
transgenic cells were 3.7104 and 5.1105 TCID50, respectively
(Fig. 4B). Therefore, the shRNAs expression in transgenic cells
inhibited about 96.15% or 92.88% of viral replication (Fig. 4C). We
concluded from this study that, expression of shRNAs targeting
VP1 gene in primary transgenic bovine tongue epithelium cells
signiﬁcantly blocked viral replication.Discussion
RNAi silencing variant viral genes could protect cells and/or
experimental animals from challenge of FMDV, and the protection
or prevention was speciﬁc and effective. Subcutaneous injection of a
multiple targeting RNAi plasmid against VP1 gene in the neck
caused suckling mice signiﬁcantly less sensitive to different sero-
types of FMDV (Chen et al., 2004; Cong et al., 2010a); recombinant
shRNA plasmids, which silenced 3D gene, protected guinea pigs
(Joyappa et al., 2009) or swine (Chen et al., 2006) from FMDV;
An attenuated Salmonella choleraesuis-mediated siRNA targeting
3D gene protected guinea pigs and swine from virus (Cong et al.,
2010b); shRNA against VP4 protected bovine epithelium cells from
virus (Wang et al., 2012). RNAi has been becoming an effective
antiviral strategy for its speciﬁc silencing of viral gene expression
and could be a viable approach to control FMD (Chen et al., 2006;
Joyappa et al., 2009). However, major issues of RNAi for prevention
of viral infection are delivery, speciﬁcity and stability of the RNAi
reagents, delivery is the biggest problem (Perrimon et al., 2010).
shRNA targeting FMDV expressed in transgenic mice could inhibit
viral replication and protect transgenic animals from virus after
challenge of FMDV (Wang et al., 2010). Therefore, production of
transgenic animals may be a useful strategy for RNAi against FMDV.
In this study, the three shRNAs, which targeted sequences of
VP1 gene of ASIA1/YS/CHA/05 strain, were screened for inhibition
of transient expression of a FLAG-VP1 protein in 293T cells at ﬁrst
(Fig. 1A). Moreover, RNAi-LT6 strongly blocked mRNA expression
of VP1 gene, and inhibited viral replication by more than 95% in
BHK-21 cells stably expressing shRNA (Fig. 1B and C). A very high
level of inhibition of virus replication may be due to selection of
stable clone of BHK-21 cells in which most cells expressed
targeting shRNAs. The transient transfection of RNAi expressing
plasmids/siRNA into BHK-21 cells was a common delivery
method (Chen et al., 2004, 2006; Cong et al., 2010a, 2010b;
Joyappa et al., 2009), with limitation of transfection efﬁciency,
shRNA/siRNA was not expressed in most cells, resulting in a
reduced inhibition of viral replication.
Transgenic cells with RNAi-LT6 from a single donor cell clone
were then transferred into enucleated oocyte cytoplasts, recon-
structed embryos were selected based on their expression of eGFP
and transferred to synchronized recipient cows. Since evaluation
of the efﬁciency of FMDV shRNA targeting after transgenic delivery
is very important, if we use adult animals, it will take a long time
and a large amount of money, so we selected 4-month-old fetuses,
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Fig. 3. RNAi-mediated degradation of viral RNA in primary transgenic bovine tongue epithelium cells: the primary bovine tongue cells were isolated from three normal
(N1, N2, N3) or three transgenic (T1, T2, T3), and inoculated with 200 TCID50 of FMDV, viral samples were taken at 0 h, 24 h and 48 h, and viral RNA was determined with
real-time RT-PCR, the relative amount viral RNA in three normal (N1, N2, N3) or three transgenic (T1, T2, T3) primary bovine tongue cells from three independent
experiments was computed using ABI Prism 7000 SDS Software (Applied Biosystems) (A), the average amount viral RNA was compared between normal (Norm) and
transgenic (Trans) groups (B), and its inhibition by shRNA in transgenic cells was evaluated as compared to normal controls (C). The standard used was 10-fold dilutions of
107 TCID50 of virus ml
1(from 101 to 107 TCID50). Duncan’s multiple range test by SAS 8.0 system, means with the same letter are not signiﬁcantly different (P40.01).
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Fig. 4. RNAi-mediated protection of primary transgenic bovine tongue epithelium cells from FMDV infection: the primary bovine tongue cells were isolated from three
normal or three transgenic fetuses, cultured in 96-well plates and inoculated with 200 TCID50 of the FMDV strain each well. Virus samples were collected at indicated time
points, and virus titer was then determined. The viral titers in three normal (N1, N2, N3) or three transgenic (T1, T2, T3) cells from three independent experiments were
presented as an average number of TCID507one standard deviation at different time (A), the average viral titers was compared between normal (Norm) and transgenic
groups (Trans) (B), and viral inhibition by shRNA in transgenic cells was calculated as 1percentage of average number of TCID50 of transgenic cells to that of normal
controls (C). Duncan’s multiple range test by SAS 8.0 system, means with the same letter are not signiﬁcantly different (P40.01).
H. Wang et al. / Virology 439 (2013) 115–121118instead of adult animals, to prepare primary tongue epithelium
cells as a model used for FMDV challenge assay in this study.
Integration of shRNA into chromosome of transgenic fetuses and
shRNA expression of primary transgenic bovine epithelium
cells were conﬁrmed by Southern hybridization and Northern
at ﬁrst, respectively, and then primary tongue epithelium cells oftransgenic bovine fetuses were inoculated with 200 TCID50 of
FMDV. The shRNA expressed in transgenic fetuses could signiﬁ-
cantly degrade viral RNA at designated time points (Fig. 3), and
blocked viral replication (Fig. 4), so primary transgenic bovine fetus
tongue epithelium cells could signiﬁcantly resist against challenge
of FMDV.
H. Wang et al. / Virology 439 (2013) 115–121 119The high speed of replication, short incubation time, and high
contagiousness is the most important threat of FMDV virus.
Therefore, although protective immune responses could be efﬁ-
cacious against FMDV, the rapidity of virus replication and spread
can outpace immune defenses development and overrun the
immune system (Summerﬁeld et al., 2009). In this study, shRNA
inhibited over 90% of viral replication after FMDV challenge
(Fig. 4), not completely blocked viral replication, but signiﬁcantly
decrease the speed of viral replication. Therefore, it will be a
useful strategy for transgenic cows to get more time to develop
immune defense. Of course, whether transgenic cows indeed
become resistant to FMDV infection will wait for the future study
using adult transgenic cows upon FMDV challenge.
Due to their high degree of sequence speciﬁcity, shRNAs
become ineffective in the presence of escape mutations within
and outside the targeted regions (Westerhout et al., 2005), and
variations within multiple regions of the quasispecies of FMDV
were retrospectively revealed by sequencing of FMDV genes.
Thus, we need to screen much more effective shRNAs targeting
FMDV using virus sensitive natural cells as a model, and it may be
important to multiplex shRNAs in a single vector (Li et al., 2005) if
RNAi is to be developed for therapeutic and preventive use.
In conclusion, we screened shRNA targeting viral VP1 gene,
and conﬁrmed its anti-viral function in primary tongue epithe-
lium cells from transgenic fetuses expressing shRNA. This
approach merits further investigation as a potential preventive
strategy for FMD control in transgenic dairy cattle.Materials and methods
Unless otherwise noted, all reagents used were obtained from
Sigma Chemical Co. (St. Louis, MO, USA). All procedures were
approved by the Shandong Academy of Agricultural Sciences
Animal Care and Use Committee.
Cells
293T cells and BHK-21 cells were grown in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Primary bovine tongue epithelium cells were
obtained as follows: small pieces from the mucosa of the tip of a
bovine tongue were used as explants to initiate a cell culture with
Iscove’s Dulbecco modiﬁed Eagle medium (DMEM) and Ham’s
F12 medium at 1:1 supplemented with 10% fetal calf serum, and
an outgrowth of polymorphic cells but mostly epithelium-like cell
types was observed.
Titration of FMDV
BHK-21 cells or primary bovine tongue cells were passaged in
96-well plates with Iscove’s Dulbecco modiﬁed Eagle medium
(DMEM) and Ham’s F12 medium at 1:1 supplemented with 10%
fetal calf serum (FCS), and infected with 10-fold dilutions of
FMDV ASIA1/YS/CHA/05 strain in four replicates per dilution
when they developed a conﬂuent monolayer. After 48 h, viral
cytopathic effect (CPE) was monitored and 50% tissue infective
dose (TCID50) of virus was calculated using the Reed–Muench
method.
Construction of shRNA recombinant lentiviral plasmids and VP1
recombinant pcDNA3
Lentivirus-based shRNA plasmids were constructed as
described previously (Chen et al., 2011). The sequences of these
of VP1 shRNA oligonucleotides are RNAi-LT4-P1: 50-GAG CAC CCAAAC CCT TGA TTT CAA GAG AAT CAA GGG TTT GGG TGC TCT TTT
TTG T-30 and RNAi-LT4-P2: 50-TAG ACA AAA AAG AGC ACC CAA
ACC CTT GAT TCT CTT GAA ATC AAG GGT TTG GGT GCT C-30;
RNAi-LT5-P1: 50-CAG TGT ACA ACG GGA AGA CTT CAA GAG AGT
CTT CCC GTT GTA CAC TGT TTT TTG T-30 and RNAi-LT5-P2: 50-CTA
GAC AAA AAA CAG TGT ACA ACG GGA AGA CTC TCT TGA AGT CTT
CCC GTT GTA CAC TG-30; RNAi-LT6-P1: 50-ACA GGA GAT CAT TGC
ACC TTT CAA GAG AAG GTG CAA TGA TCT CCT GTT TTT TTG T-30
and RNAi-LT6-P2: 50-CTA GAC AAA AAA ACA GGA GAT CAT TGC
ACC TTC TCT TGA AAG GTG CAA TGA TCT CCT GT-30; RNAi-LT4,
RNAi-LT 5, and RNAi-LT were constructed corresponding to
nucleotides from 3399 to 3417, from 3644 to 3662, or from
3861 to 3879 of ASIA1/YS/CHA/05 strain (GenBank Accession no.
GU931682.1). The control shRNA sequences are LacZ-P1: 50-CAG
TTG CGC AGC CTG AAT GTT CAA GAG ACA TTC AGG CTG CGC AAC
TGT TTT TTG T-30 and LacZ-P2: 50-CTA GAC AAA AAA CAG TTG CGC
AGC CTG AAT GTC TCT TGA ACA TTC AGG CTG CGC AAC TG-30.
The sequence of LacZ shRNA was not homologous to those of viral
genes, so shRNA of LacZ recombinant lentivirus was negative
shRNA control. These oliognucleotides were annealed to each
other and ligated into H1 lentiviral plasmid, followed by DNA
sequence conﬁrmation. The PCR primer pair was LT1: 50-TGT
CGCTATGTGTTCTGGGA-30 and LT2: 50-GGT ACA GTG CAG GGG
AAA GA-30.
VP1 recombinant pcDNA3 plasmid was constructed. The PCR
primer pair used for pcDNA3-Flag-VP1 was VP1-P1: 50-GGG GTA
CC G CCA CCA TGG ACT ACA AGG ACG ACG ATG ACA CTA CCA CCA
CTG GCG AGT-30 and VP1-P2: 50-GCT CTA GAT TAC TGT TTC TCA
GGT GCA-30; PCR fragments were digested with Kpn I and Xba I,
and subcloned into previously digested pcDNA3, followed by DNA
sequence conﬁrmation.
Co-transfection of lentiviral shRNAs and FLAG-tagged VP1 gene
in 293T cells
Five microgram of pcDNA3-FLAG-VP1 was co-transfected into
293T cells with 5 mg of recombinant shRNA lentiviral plasmids,
using Lipofectamine 2000, according to manufacturer’s instruc-
tion (Invitrogen). After 48 h, transient expression of the FLAG-VP1
protein was determined by Western Blot, performed as described
previously (He and Sun, 2007). In brief, 293T cells were lysed
using Lysis Buffer (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1%
Triton, 5 mM EGTA, 5 mM EDTA, 1 mM NaF, 1 mM Na3VO4,
freshly added proteinase inhibitor tablet) and supernatants were
collected by centrifugation. Proteins were separated on polyacry-
lamide gels in the presence of SDS and electrophoretically
transferred onto nitrocellulose membrane. The membranes were
blocked with 5% Blotto in TBS-T (20 mM Tris–HCl, pH 7.4,
150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature and
probed with various antibodies against FLAG and b-actin (Sigma).
Speciﬁc proteins were visualized by ECL (Amersham Biosciences)
detection, size of FLAG-VP1 and b-actin was about 21 kD or 40 kD,
respectively. VP1 expression was quantiﬁed relative to the LacZ
shRNA control.
Establishment of shRNA transgenic BHK-21 cells and FMDV infection
Five microgram of recombinant shRNA lentiviral plasmids was
transfected into BHK-21 cells using Lipofectamine 2000, accord-
ing to manufacturer’s instruction (Invitrogen). The cells were
subcultured after 48 h, and stable cell lines with shRNAs were
screened by FACS analysis based on shRNA recombinant H1
lentivirus encoding eGFP. The stable cell lines with RNAi-LT4,
RNAi-LT5, RNAi-LT6 or LacZ shRNA were cultured in 12-well
plates in four replicates, and 4105 cells at each well were
inoculated with the FMDV ASIA1/YS/CHA/05 strain at 200 TCID50
H. Wang et al. / Virology 439 (2013) 115–121120(about 0.00025 multiplicities of infection (MOI)). After 48 h, CPE
of each well was measured. Cells and supernatant were collected
for assessment of shRNA gene silencing efﬁciency and FMDV titer.
The mRNA expression of VP1 gene and b-actin in cells transfected
with recombinant shRNA was detected by RT-PCR. Total RNA was
isolated from the cells with TRIzol reagent (Promega). The cDNA
was synthesized using VP1-P2 and Oligo dT as primers and
Moloney Murine Leukemia Virus reverse transcriptase (Promega)
in the reverse transcription reaction. Ampliﬁcation was per-
formed using the following primer pairs: VP1-P1 and VP1-P2 for
VP1 (674 bp), and b-actin-P1: 50-GAT ATG GAG AAG ATC TGG CA-30
and b-actin-P2: 50-GTT GAA TGT AGT TTC GTG GA-30 for b-actin
(598 bp). Ampliﬁed cDNA was analyzed with 1% agarose gel
electrophoresis.
Preparation of transgenic donor cells
Donor cell lines were established from a 50-days fetus of
Holstein cow as described previously (Wu et al., 2012). Tissue
was minced, suspended in DMEM/Ham’s F12 (1:1) supplemented
with 15% FBS and antibiotics, seeded in 25 cm2 tissue culture
ﬂasks, and cultured at 37 1C in a humidiﬁed atmosphere of 5% CO2
in air for several days. 10 mg of shRNA recombinant lentiviral
plasmid RNAi-LT6 was transfected into bovine fetal ﬁbroblast cells
using Lipofectamine 2000 according to manufacturer’s instruction
(Invitrogen). After 48 h, the cells were sorted by ﬂuorescence-
activated cell sorter (FACS) analysis based on eGFP co-expression in
the viral plasmid, and subcultured in 96-well plate, about 0.7 cell
per well. 14 days later, transgenic bovine fetal ﬁbroblast cell clones
were selected based on eGFP expression, and conﬁrmed by PCR
with primer pair LT1/LT2 and DNA sequencing.
Oocyte in vitro maturation (IVM)
Oocytes were maturated in vitro as described previously
(Wu et al., 2012). Bovine ovaries were collected from a local
abattoir and cumulus-enclosed oocyte complexes were aspirated
from 3 to 8 mm follicles. Oocytes with evenly shaded cytoplasm
and intact layers of cumulus cells were selected and cultured in
maturation medium: M199 containing 10% fetal bovine serum
(FBS; HyClone Laboratories, Logan, UT), 0.5 mg/ml FSH (Sioux
Biochemicals, Sioux City, IA), 5 mg/ml LH (Sioux Biochemicals),
100 U/ml penicillin and 100 mg/ml streptomycin (HyClone
Laboratories, Logan, UT) and cultured for 20 h prior to nuclear
transfer.
Nuclear transfer
Routine manipulations were previously described (Wu et al.,
2012). After maturation for 20 h, the cumulus cells were removed
and oocytes with the ﬁrst polar body were enucleated as cytoplast
recipients. Single transfected cells were transferred to the perivi-
telline space of enucleated oocytes. The reconstructed couplets
were fused in mannitol fusion buffer by two DC pulses of 1.8 kV/cm
for 20 ms. Then the fused clones were activated by 5 mM ionomycin
for 5 min and treated with 10 mg/ml cycloheximide in CR1aa
medium for 5 h in 5% CO2 in air at 38 1C. Following activation, the
embryos were cultured in CR1aa medium supplemented with BSA
for 40 h, then the cleaved embryos were transferred and cultured in
CR1aa medium plus 4% FBS feeding with a single layer cumulus
cells under 5% CO2 in air at 38 1C with high humidity.
Embryo transfer
On day six or seven, compacted morulae and blastocysts were
shipped overnight in equilibrated CR2 at 38.5 1C to the site oftransfer. Two embryos were transferred nonsurgically to cows
synchronized one day to the stage of embryonic development.
Pregnancy was detected by transrectal ultrasound at embryonic
days 60, and pregnant recipients were checked by ultrasound or
palpation at approximately 30-days intervals to conﬁrm ongoing
pregnancies, and fetuses were obtained with surgery at four
months.
shRNA integration into chromosome of cloned bovine fetuses
The genomic DNA from the ear tissue of 4-month-old cloned
and normal fetuses were extracted according to standard mole-
cule cloning instructions, and used as the template for PCR
ampliﬁcation with LT1/LT2 primer pair, then shRNA transgenic
fragment (about 300 bp) was conﬁrmed by DNA sequencing.
Up and Down primers of probe for Southern Blotting were
designed according to the ﬂanking sequence of shRNA in shRNA
recombinant H1 Lenti-virus vector, Up primer 1: 50-GAA GAA CGG
CAT CAA GGT G-30; Down primer: 50-TTG CTT CCC GTA TGG CTT-30;
The shRNA recombinant H1 Lenti-virus vector was used for
template to amplify 414 bp probe labeling with Invitrogen Plati-
nums Tag Kit. The genomic DNAs from the cloned and normal
fetus were digested into smaller fragments with excess amounts
of XhoI and ApaI for 18 h. The concentrated samples were
hybridized with probe as standard protocol, and 3.6 kb of trans-
genic positive band was determined.
shRNA expression in primary bovine tongue epithelium cells
Total RNA was isolated from the cells with TRIzol reagent
(Promega). Ten microgram (mg) of total RNA were then size
fragmented by electrophoresis on 1.5% agarose/formaldehyde
gel, transferred onto Nitrocellulose membrane, prehybridized,
and hybridized according to the method of Church and Gilbert
(Church and Gilbert, 1984). The cDNA was prepared with Super-
Script. III First-Strand Synthesis System (invitrogen) from the
total RNA using oligo dT primer. Up primer of bovine b-actin:
50-AGC AAG CAG GAG TAC GAT GAG-30, Down primer of bovine
b-actin: 50-TGC CAA TCT CAT CTC GTT TTC-30, and cDNA was used
for template to amplify 313 bp of b-actin fragment. The shRNA
probe was artiﬁcially synthesized as follows, sense chain: 50-ACA
GGA GAT CAT TGC ACC T-30, anti-sense chain: 50-AGG TGC AAT
GAT CTC CTG T-30, and then was annealing to double strain probe
of shRNA. The complementary DNA probes were labeled with
rediprimerTM II random primer labeling system (amersham) to
yield a speciﬁc activity of 2–5108 cpm/mg, and used at a
concentration of 106 cpm/ml hybridization solution. The ﬁnal
posthybridization wash was performed four times at 65 1C for
10 min each time with a solution containing 1% SDS, 1 mM EDTA,
and 20 mM sodium phosphate, pH 7.2. The membranes were then
exposed to X-ray ﬁlm (Kodak) with intensifying screens at
80 1C. For the reprobing, the original probe was removed by
treating the membranes with boiling water for 10 min.
FMDV infection in primary bovine tongue epithelium cells
2105 of the primary normal or transgenic bovine tongue
cells cultured in 12-well plates were inoculated with viruses at
200 TCID50 (about 0.005 MOI) each well, after 1 h absorption, the
medium was changed with fresh medium without FCS, and virus
samples were collected at designated time points and frozen at
80 1C until for assessment of FMDV titer and viral RNA.
The viral RNA was isolated from virus sample using a TRIzol kit
(Invitrogen), and cDNA was prepared with SuperScript III First-
Strand Synthesis System (invitrogen) and RT primers for viral RNA
as follows, R1 50-CTC TGT AGT CAC TGT CTG TC-30, and oligo dT for
H. Wang et al. / Virology 439 (2013) 115–121 121bovine b-actin. The cDNA then was subjected to real-time RT-PCR
analysis, according to the manufacturer’s instruction of Quanti-
Tect SYBR green RT-PCR kit (Qiagen). Cycling program was set as
following: 95 1C for 10 min for the PCR initial activation and 40
cycles of denaturation at 95 1C for 15 s, annealing and extension
at 60 1C for 1 min. PCR primer pair were used as follows, R1 and
F1: 50-CAA AAG ATG GTC ATG GGC-30 for viral RNA. The standard
used was 10-fold dilutions of 107 TCID50 of virus ml
1. All further
computations were done using ABI Prism 7000 SDS Software
(Applied Biosystems). The statistical analysis was based on data
from three independent experiments.Acknowledgments
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